Literature DB >> 3880867

High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.

C G Moertel, T R Fleming, E T Creagan, J Rubin, M J O'Connell, M M Ames.   

Abstract

It has been claimed that high-dose vitamin C is beneficial in the treatment of patients with advanced cancer, especially patients who have had no prior chemotherapy. In a double-blind study 100 patients with advanced colorectal cancer were randomly assigned to treatment with either high-dose vitamin C (10 g daily) or placebo. Overall, these patients were in very good general condition, with minimal symptoms. None had received any previous treatment with cytotoxic drugs. Vitamin C therapy showed no advantage over placebo therapy with regard to either the interval between the beginning of treatment and disease progression or patient survival. Among patients with measurable disease, none had objective improvement. On the basis of this and our previous randomized study, it can be concluded that high-dose vitamin C therapy is not effective against advanced malignant disease regardless of whether the patient has had any prior chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3880867     DOI: 10.1056/NEJM198501173120301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  163 in total

Review 1.  New insights into the physiology and pharmacology of vitamin C.

Authors:  S J Padayatty; M Levine
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

2.  Proof versus plausibility: rules of engagement for the struggle to evaluate alternative cancer therapies.

Authors:  L J Hoffer
Journal:  CMAJ       Date:  2001-02-06       Impact factor: 8.262

3.  Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions?

Authors:  J S McLay; D Stewart; J George; C Rore; S D Heys
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

4.  Clinical studies with make-believe drugs.

Authors:  J P Lewis
Journal:  West J Med       Date:  1992-12

Review 5.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

Review 6.  Targeting cancer vulnerabilities with high-dose vitamin C.

Authors:  Bryan Ngo; Justin M Van Riper; Lewis C Cantley; Jihye Yun
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

7.  Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues.

Authors:  Qi Chen; Michael Graham Espey; Murali C Krishna; James B Mitchell; Christopher P Corpe; Garry R Buettner; Emily Shacter; Mark Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

8.  TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.

Authors:  Xiaojing Yue; Anjana Rao
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

Review 9.  Vitamin C in Stem Cell Reprogramming and Cancer.

Authors:  Luisa Cimmino; Benjamin G Neel; Iannis Aifantis
Journal:  Trends Cell Biol       Date:  2018-04-30       Impact factor: 20.808

10.  Pharmacological Ascorbate as an Adjuvant for Enhancing Radiation-Chemotherapy Responses in Gastric Adenocarcinoma.

Authors:  Brianne R O'Leary; Frederick K Houwen; Chase L Johnson; Bryan G Allen; James J Mezhir; Daniel J Berg; Joseph J Cullen; Douglas R Spitz
Journal:  Radiat Res       Date:  2018-03-16       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.